Anticholinergics in the era of atypical antipsychotics: Short-term or long-term treatment?

Journal of Psychopharmacology

Volumn 26, Issue 9, 2012, Pages 1167-1174

  Desmarais, Julie Eve ^a,b   Beauclair, Linda ^a,b   Margolese, Howard C ^a,b  

^a Allan Memorial Institute   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

anticholinergics; antipsychotics; cognition; Extrapyramidal symptoms; movement disorders; schizophrenia

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPHENHYDRAMINE; FLUPHENAZINE; NEUROLEPTIC AGENT; ORPHENADRINE; PIPOTIAZINE; PLACEBO; PROCYCLIDINE; PROFENAMINE; PROMETHAZINE; TRIHEXYPHENIDYL;

AKINESIA; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SCHIZOPHRENIA; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; DRUG INTERACTIONS; DRUG MONITORING; DYSKINESIA, DRUG-INDUCED; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MENTAL DISORDERS; NEUROTOXICITY SYNDROMES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 84864979711     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112447988     Document Type: Article

References (73)

1. Ananth JV, Horodesky S, Lehmann HE, et al. Effect of withdrawal of antiparkinsonian medication on chronically hospitalized psychiatric patients. Laval Med. 1970 ; 41: 934-938
2. Baker LA, Cheng LY, Amara IB. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry. 1983 ; 143: 584-590
3. Barsoum A, Kolivakis TT, Margolese HC, et al. Diphenhydramine (Unisom), a central anticholinergic and antihistaminic: abuse with massive ingestion in a patient with schizophrenia. Can J Psychiatry. 2000 ; 45: 846-847
4. Ben Hadj Ali B, Dogui M, Ben Ammou S, et al. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal]. Encephale. 1995 ; 21: 209-215
5. Betermiez P, Delahousse J, Pedinielli JL. [Anticholinergics during neuroleptic treatment. Value and withdrawal]. Encephale. 1986 ; 12: 169-174
6. Bezchlibnyk-Butler K, Jeffries J, Virani A Clinical Handbook of Psychotropic Drugs. Hogrefe and Huber Publishers ; 2009 :
7. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010 ; 36: 71-93
8. Burgyone K, Aduri K, Ananth J, et al. The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms. Curr Pharm Des. 2004 ; 10: 2239-2248
9. Burnett GB, Prange AJ, Wilson IC, et al. Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism. Neuropsychobiology. 1980 ; 6: 109-120
10. Cahan RB, Parrish DD. Reversibility of drug-induced parkinsonism. Am J Psychiatry. 1960 ; 116: 1022-1023
11. Cancelli I, Beltrame M, Gigli GL, et al. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci. 2009 ; 30: 87-92
12. Caplan JP, Epstein LA, Quinn DK, et al. Neuropsychiatric effects of prescription drug abuse. Neuropsychol Rev. 2007 ; 17: 363-380
13. Caradoc-Davies G, Menkes DB, Clarkson HO, et al. A study of the need for anticholinergic medication in patients treated with long-term antipsychotics. Aust N Z J Psychiatry. 1986 ; 20: 225-232
14. Caroli F, Littre-Poirier MF, Ginestet D, et al. Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics. Encephale. 1975 ; 1: 69-74
15. Carter G. The abrupt withdrawal of antiparkinsonian drugs in mentally handicapped patients. Br J Psychiatry. 1983 ; 142: 166-168
16. Chien CP, Castaldo V, Thornton A, et al. Prophylactic usage of antiparkinsonian drugs for akinesia [proceedings]. Psychopharmacol Bull. 1979 ; 15: 75-78
17. Chien CP, Dimascio A, Cole JO. Antiparkinsonian agents and depot phenothiazine. Am J Psychiatry. 1974 ; 131: 86-90
18. Chouinard G, De Montigny C, Annable L. Tardive dyskinesia and antiparkinsonian medication. Am J Psychiatry. 1979 ; 136: 228-229
19. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005 ; 76: 247-265
20. DiMascio A, Demirgian E. Antiparkinson drug overuse. Psychosomatics. 1970 ; 11: 596-601
21. Double DB, Warren GC, Evans M, et al. Efficacy of maintenance use of anticholinergic agents. Acta Psychiatr Scand. 1993 ; 88: 381-384
22. Drimer T, Shahal B, Barak Y. Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. Int Clin Psychopharmacol. 2004 ; 19: 27-29
23. Fleischhauer J. Open withdrawal of antiparkinson drugs in the neuroleptic-induced Parkinson syndrome. Int Pharmacopsychiatry. 1975 ; 10: 222-229
24. Galletly C. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl). 2009 ; 202: 259-273
25. Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008 ; 69: 302-309
26. Gerlach J, Thorsen K. Movement pattern of oral tardive-dyskinesia in relation to anticholinergic and antidopaminergic treatment. Int Pharmacopsychiatry. 1976 ; 11: 1-7
27. Good MI. Reversibility of long-term tardive dyskinesia associated with antiparkinsonian medication: a case report. Am J Psychiatry. 1981 ; 138: 1112-1113
28. Greil W, Haag H, Rossnagl G, et al. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry. 1984 ; 145: 304-310
29. Grove L, Crammer JL. Benzhexol and side effects with long-acting fluphenazine therapy. Br Med J. 1972 ; 1: 276-279
30. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008 ; 23: 15-26
31. Horiguchi J, Nishimatsu O. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study. Jpn J Psychiatry Neurol. 1992 ; 46: 733-739
32. Jellinek T, Gardos G, Cole JO. Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry. 1981 ; 138: 1567-1571
33. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006 ; 63: 1079-1087
34. Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003 ;: CD003735
35. Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1974 ; 37: 941-947
36. Klett CJ, Caffey E. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Arch Gen Psychiatry. 1972 ; 26: 374-379
37. Korczyn AD, Goldberg GJ. Extrapyramidal effects of neuroleptics. J Neurol Neurosurg Psychiatry. 1976 ; 39: 866-869
38. Kosma K, Roumbos B, Mamali M, et al. Poster sessions. P.3.c.061 Neuroleptic malignant syndrome after abrupt withdrawal of anticholinergic agents: case report. Eur Neuropsychopharmacol. 2008 ; 18 :
39. Lavin MR, Rifkin A. Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy. J Clin Pharmacol. 1991 ; 31: 769-777
40. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 ; 353: 1209-1223
41. Mandel W, Claffey B, Margolis LH. Recurrent thioperazine-induced extrapyramidal reaction following placebo substitution for maintenance antiparkinson drug. Am J Psychiatry. 1961 ; 118: 351-352
42. Mandel W, Oliver WA. Withdrawal of maintenance antiparkinson drug in the phenothiazine-induced extrapyramidal reaction. Am J Psychiatry. 1961 ; 118: 350-1
43. Manos N, Gkiouzepas J. Discontinuing antiparkinson medication in chronic schizophrenics. At what cost to the patient?. Acta Psychiatr Scand. 1981 ; 6 (1). 28-32
44. Manos N, Gkiouzepas J, Logothetis J. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. Am J Psychiatry. 1981a ; 138: 184-188
45. Manos N, Gkiouzepas J, Tzotzoras T, et al. Gradual withdrawal of antiparkinson medication in chronic schizophrenics: any better than the abrupt?. J Nerv Ment Dis. 1981b ; 169: 659-661
46. McClelland HA, Blessed G, Bhate S, et al. The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients. Br J Psychiatry. 1974 ; 124: 151-159
47. McEvoy JP. The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J Clin Psychopharmacol. 1983 ; 3: 288-302
48. McInnis M, Petursson H. Withdrawal of trihexyphenidyl. Acta Psychiatr Scand. 1985 ; 71: 297-303
49. Mindham RH, Gaind R, Anstee BH, et al. Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced parkinsonism. Psychol Med. 1972 ; 2: 406-413
50. Mori K, Yamashita H, Nagao M, et al. Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry. 2002 ; 35: 6-11
51. Mufson EJ, Ginsberg SD, Ikonomovic MD, et al. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat. 2003 ; 26: 233-242
52. Ogino S, Miyamoto S, Tenjin T, et al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35: 78-83
53. Olivera AA, Evans M. Chronic anticholinergic administration-dependence, withdrawal syndrome, and treatment. Curr Ther Res Clin Exp. 1988 ; 44: 325-328
54. Orlov P, Kasparian G, DiMascio A, et al. Withdrawal of antiparkinson drugs. Arch Gen Psychiatry. 1971 ; 25: 410-412
55. Pecknold JC, Ananth JV, Ban TA, et al. Lack of indication for use of antiparkinson medication. A follow-up study. Dis Nerv Syst. 1971 ; 32: 538-541
56. Perenyi A, Gardos G, Samu I, et al. Changes in extrapyramidal symptoms following anticholinergic drug withdrawal. Clin Neuropharmacol. 1983 ; 6: 55-61
57. Rashkis HA, Smarr ER. Protection against reserpine-induced parkinsonism. Am J Psychiatry. 1957 ; 113: 1116
58. Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2006 ; 4: CD003727
59. Rifkin A, Quitkin F, Kane J, et al. Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. Arch Gen Psychiatry. 1978 ; 35: 483-489
60. Saran AS. Use or abuse of antiparkinsonian drugs by psychiatric patients. J Clin Psychiatry. 1986 ; 47: 130-132
61. Smith JM. Abuse of the antiparkinson drugs: a review of the literature. J Clin Psychiatry. 1980 ; 41: 351-354
62. Spivak B, Gonen N, Mester R, et al. Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents. Int Clin Psychopharmacol. 1996 ; 11: 207-209
63. St. Jean A, Donald M, Ban TA. Interchangeablity of antiparkinsonian medication. Am J Psychiatry. 1964a ; 120: 1189-1190
64. St. Jean A, Donald MW, Ban TA. Uses and abuses of antiparkinsonian medication. Am J Psychiatry. 1964b ; 120: 801-803
65. Stanilla J, Simpson G The American Psychiatric Publishing Textbook of Psychopharmacology. 2009 ) Drugs to treat extrapyramidal side effects. In: The American Psychiatric Publishing Textbook of Psychopharmacology. Fourth ed.Ch. 34. American Psychiatric Publishing Inc. American Psychiatric Publishing Inc ; 2009 :
66. Straker M. Clinical factors in tardive-dyskinesia. Psychiatr J Univ Ott. 1980 ; 5: 28-33
67. Stratas NE, Phillips RD, Walker PA, et al. A study of drug-induced parkinsonism. Dis Nerv Syst. 1963 ; 24: 180
68. Terry AV. Role of the central cholinergic system in the therapeutics of schizophrenia. Curr Neuropharmacol. 2008 ; 6: 286-292
69. Ungvari GS, Chiu HF, Lam LC, et al. Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol. 1999 ; 19: 141-148
70. Vinogradov S, Fisher M, Warm H, et al. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009 ; 166: 1055-1062
71. Wada Y, Koshino Y, Yamaguchi N. Biperiden withdrawal in schizophrenic inpatients receiving long-term antipsychotic medication. Clin Neuropharmacol. 1987 ; 10: 370-375
72. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. Br J Psychiatry. 1990 ; 156: 412
73. Yassa R. Antiparkinsonian medication withdrawal in the treatment of tardive dyskinesia: a report of three cases. Can J Psychiatry. 1985 ; 30: 440-442